Protect Your Patients with the PtProtect® Pain Management Program

Opioid analgesics have a legitimate and important role to manage pain. Yet the use and abuse of prescription medications continues to be a challenge.
 
Drug overdose death rates in the United States have more than tripled since 1990, from 2.3 to 10.8 per 100,000 and continue to climb.1 Nearly three out of four prescription drug overdoses are caused by prescription painkillers.  According to the Centers for Disease Control and Prevention (CDC), 46 people die from an overdose of prescription painkillers every day in the United States.
 
An accurate determination of a patie​nt's medication intake is critical to patient safety. Our most data shows nearly 42 percent of the time, a patient's urine drug test result will disclose information not explained by the patient's known pain medication prescriptions.
 

With the PtProtect® ('Patient Protect') Pain Management Program, you get confidence and reliability to ensure successful pain medication monitoring.

Comprehensive

  • ​Detects up to 38 prescribed medications and illicit drugs, reducing the possibility of adverse  drug reactions and identifying potential diversion of medications.

Sensitive

  • Uses Liquid Chromatography/Tandem Mass Spectometry (LC-MS/MS) and the lowest available detection thresholds for the most accurate and sensitive opiate/opioid testing.  Our data shows that up to 30 percent of drugs found by LC-MS/MS would have been missed using conventional immunoassay screens or point of care drug tests for opiates and opioids.

Interpretive

  • Analytical reports and easy-to-understand interpretive comments eliminate guesswork and saves you time.

The PtProtect® difference:

  • ​Monitors analgesic medication adherence to ensure patient safety and protect your practice
  • Uses lowest detection thresholds (2-5 ng/mL) for the most sensitive, comprehensive detection of opiates and opioids
  • Offers highest testing specificity available
  • Expert toxicologists available for consult and face-to-face meetings
  • Four comprehensive panel configurations detect up to 38 prescribed medications and illicit drugs
  • Detects non-prescribed analgesic medication, reducing the possibility of adverse drug interactions
  • Employs LC-MS/MS technology to detect opiates and opioids, avoiding false negatives that may result from an immunoassay screen test or point-of-care drug screen
  • Simplifies patient management with easy-to-understand interpretations in addition to quantitative results
  • Clinic-specific Discrepancy Reports provide a snapshot of your patient population's compliance to their prescription regimen over a specific time period.  The report also details how your clinic's discrepancy rate compares with PeaceHealth Laboratories' average rate of patient medication compliance

Find Out More:

Media and Press Attention

Video June 10, 2015 - The Importance of Laboratory Testing for Risk Assessment, Expert Opinion from Jennifer Bolen, JD (painweek.org) 

 
Blog March 26, 2015 - It's Time to Act to Reduce Opioid Related Injuries and Deaths, United States Health and Human Services (HHS) Secretary Sylvia Mathews Burwell
 
Press Release March 26, 2015 - HHS takes strong steps to address opioid-drug related overdose, death, and dependence
 
 
 

Public Radio June 4, 2012 - Fighting Overdose with the PtProtect® Pain Management Program, interview with PeaceHealth Laboratories CEO Ran Whitehead and Clinical Toxicologist Grant Beardsley (Jefferson Exchange, South Oregon University)  

Press Release May 30, 2012 - PeaceHealth Laboratories' New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse

Reference​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

1 Washington State Dept of Health: Washington State Injury and Violence Prevention Guide, January 2013, DOH 530-090.​​​

​​